DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $40.25.

Several analysts have recently commented on DBVT shares. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Guggenheim restated a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research note on Monday, May 4th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Finally, Citizens Jmp upped their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, May 1st.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors have recently bought and sold shares of the company. Allworth Financial LP bought a new stake in DBV Technologies during the 4th quarter valued at $32,000. New York State Common Retirement Fund bought a new stake in DBV Technologies during the 3rd quarter valued at $34,000. Royal Bank of Canada bought a new stake in DBV Technologies during the 4th quarter valued at $34,000. GAMMA Investing LLC raised its holdings in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the period. Finally, Truvestments Capital LLC raised its holdings in DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after acquiring an additional 1,620 shares during the period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Price Performance

Shares of DBVT opened at $18.18 on Monday. The stock has a 50-day moving average of $20.14 and a 200-day moving average of $19.24. The company has a market cap of $1.08 billion, a PE ratio of -4.08 and a beta of -0.96. DBV Technologies has a one year low of $7.53 and a one year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. Analysts expect that DBV Technologies will post -0.47 EPS for the current fiscal year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.